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1. Introduction  
SLE is the classical model of a chronic multi-systemic immune-mediated inflammatory 
disease. It affects mainly young women, a subgroup of the general population usually free 
of cardiovascular risk.  Although survival rates have improved dramatically, mainly due to 
early diagnosis, improved treatment, and better management of complications, death rates 
for patients with SLE remain 3 to 5 times higher than in the general population (Haque & 
Bruce, 2009). Nevertheless, whilst the 5-year survival of SLE was below 50% in the 1950s, it 
is nowadays above 90% (Nikpour et al., 2005).  
Atherosclerosis in SLE is a highly complex process with autoimmunity, local and systemic 
inflammation, and endothelial dysfunction playing critical roles in its initiation and 
propagation. In the particular case of SLE, the extremely intricate immune system 
deregulation involving all types of immune cells up to an increased autoantibody 
production seems to play a major role for the accelerated atheroma formation found in these 
patients.  
Cardiovascular events are now the major cause of morbidity and mortality in SLE. The 
acceptance of the importance of vascular risk in this context came from the description of a 
bimodal mortality pattern (Urowitz et al., 1976), with the early peak (within 1 year of 
diagnosis) as a consequence of active lupus and its complications, and the later peak (more 
than 5 years after diagnosis) mainly attributable to atherosclerosis. SLE is now considered to 
be a coronary heart disease-risk equivalent, mainly due to accelerated atherosclerosis 
(Aranow & Ginzler, 2000; Bjornadal et al., 2004; Manzi et al., 1997; Esdaile et al., 2001; 
Fischer et al. 2004; Roman et al., 2003; Ward, 1999).  This can be especially relevant in young 
women, where up to a 50-fold increase in cardiovascular risk over age and gender-matched 
controls has been reported (Manzi et al., 1997). In fact, the majority of those women were 
aged less than 55 years at the time of their first cardiac event.  
Framingham risk factors do not explain entirely the atherosclerotic burden found in  
patients with SLE. Furthermore, traditional cardiovascular risk factors seem to be less 
important predictors of cardiovascular events than the activity of lupus (Esdaile et al., 2001). 
(see table 1). 
The direct relation between conventional and SLE-related risk factors and the actual 
incidence of events has not been easy to establish for different reasons: most patients with 
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SLE are young or middle-age women, for whom the background rate of cardiovascular 
disease is low, SLE cohorts are small, the number of observed coronary heart disease events 
is also reduced, and may not provide statistical power for testing their associations with 
hypothetical SLE-specific risk factors ( Karp et al., 2008). This is the main reason why recent 
studies are considering surrogate markers of cardiovascular risk, such as the presence of 
carotid plaques, coronary artery calcification and vascular stiffness.  
 
TRADITIONAL RISK 
FACTORS 
INFLAMMATION-
RELATED  RISK 
FACTORS 
SLE-RELATED RISK 
FACTORS 
Genetics  
Gender 
Post-menopausal status 
Hypertension 
Dyslipidemia 
Diabetes mellitus 
Smoking 
Obesity 
Homocysteine 
Sedentary life-style 
Vascular endothelial growth 
factor 
Monocyte chemoattractant 
protein-1 
TNF-ǂ, IL-1, IL-6 
VCAM-1, ICAM-1 
Matrix –degrading proteases 
Acute phase reactants 
Vascular endothelial growth 
factor 
Monocyte chemoattractant 
protein-1 
TNF-ǂ, IL-1, IL-6 
VCAM-1, ICAM-1 
Matrix –degrading proteases 
Duration of disease 
Disease activity 
Disease damage 
Corticosteroids 
Auto-antibodies  
Complement activation 
Lupus nephritis 
Increased oxidative stress 
Table 1. Proposed cardiovascular risk factors in SLE 
Both SLE-specific and non-specific mechanisms have been proposed to play a prominent 
role in the induction of premature vascular damage, but the exact etiology remains unclear. 
Chronic inflammation is a very appellative contributor for atherosclerosis, since the 
pathogenesis of the latter is, in part, mediated by inflammation (Ross, 1999). 
A potential confounding factor is that clinically active lupus may also manifest itself with 
vascular inflammation and thrombosis in any vascular territory. However, when a 
significant large population is considered, premature vascular disease in SLE is not, as 
previously thought, just attributable to vasculitis. Actually, it presents mostly as premature 
atherosclerosis (Bacon et al., 2002; Ward, 1999), both clinically and histologically. Many 
authors believe that the rapid and progressive nature of vascular injury in patients with SLE 
makes this population ideal for the identification of mechanisms involved in general 
atherosclerosis and vascular damage.  
This chapter aims at elucidating why patients with SLE are at high risk for cardiovascular 
events, what different types of vascular conditions may be more commonly found, and what 
treatments are more likely to help overcome such burden. 
2. Burden of disease   
Despite the fact that the overall survival of patients with SLE has reached over 90% in recent 
decades, the long term survival rate has not changed since the 1980s (Petri, 2002). SLE patients 
have mortality rates of 5-10% at 5 years and 15-30% at 10 years (Abu-Shakra et al., 1995; 
Jacobsen et al., 1998; Ståhl-Hallengren et al., 2000; Uramoto et al., 1999). This is particularly 
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overwhelming in patients aged less than 55 years (Abu-Shakra et al., 1995). After the 
identification of the bimodal pattern of mortality in SLE, a more recent uptade from the 
Toronto group (Nikpour, 2005) showed that sudden death, congestive heart failure and 
vascular events are responsible for nearly 30% of late deaths in their SLE cohort. Currently, 
cardiovascular disease alone accounts for 20 to 30 % of deaths in patients with SLE (Rubin et 
al., 1985). Even with all-cause mortality declining during the last 20 years the risk of 
cardiovascular death remains unchanged. With the advent of more potent 
immunosuppressive and anti-inflammatory treatments, it is likely that the contribution of 
cardiovascular disease to morbidity and mortality in these patients will increase even further. 
Using myocardial perfusion scintigraphy, subclinical coronary atherosclerosis can be 
present in 28-38% of patients with SLE (Manger et al., 2003; Sella et al., 2003) and the 
prevalence of symptomatic coronary heart disease (as defined by angina and myocardial 
infarction) ranges from 6,6% to 20% (Gladman & Urowitz, 1987; Jonsson et al., 1989; Manzi 
et al., 1997) . Women with SLE in the 35-44 year age group are over 50 times more likely to 
have a myocardial infarction than women of similar age in the Framingham Offspring Study 
(Manzi et al., 1997). The mean age at a first coronary event is 49 years in patients with SLE 
compared with 65-74 years in the general population, as the risk of development of coronary 
heart disease in the first decade after diagnosis is approximately 12% (Bruce et al., 1999).  
There are significant racial disparities regarding age at the time of first hospital admission 
for a cardiovascular event and cardiovascular-related hospitalization resulting in death in 
patients with SLE (Scalzi et al., 2010). African-origin, in particular, is associated in an 
independent fashion with a worsened probability of survival.  
The outcomes of hospitalization for acute myocardial infarction were thought to be identical 
between patients with and without SLE, despite women with SLE being less likely to 
undergo coronary artery bypass grafting (Ward, 2004).  Whether this is due to a decreased 
need for the procedure or whether reflects a decreased referral or reduced access to the 
surgery, is not established. More recently it has been recognized that, like diabetes mellitus, 
SLE increases the risk of poor outcomes after acute myocardial infarction, and these patients 
should be considered for aggressive treatment. In fact, the risk for prolonged hospitalization 
is even higher for patients with SLE (OR 1.48, 95% CI 1.32-1.79) compared to those with 
diabetes mellitus (OR 1.30, 95% CI 1.28-1.32) (Shah et al., 2009). 
Cerebrovascular disease has been identified in 2-15% of patients with SLE (Hermosillo-
Romo & Brey, 2002; Manzi et al., 1999; Mok et al., 2001; Sanna et al., 2003), with a reported  
2-10 times higher risk for stroke SLE (Jonsson et al., 1989; Manzi et al., 1997; Ward, 1999). A 
recent prospective study showed that the cumulative incidence of arterial thromboembolism 
in new-onset Caucasian SLE patients is 5,1%, with ischemic stroke and transient ischemic 
attack comprising 65% of them (Mok et al., 2005) . Cardiovascular risk is even higher in 
lupus patients who also have secondary antiphospholipid syndrome (APS), due to the 
additive effects of SLE- and APS-related risk factors. In fact, as APS is also related to 
accelerated atherosclerosis, it may be difficult to differentiate between SLE- and APS-
associated risk factors in these patients. 
3. Vascular disease in systemic lupus erythematosus 
3.1 Atherosclerosis  
3.1.1 Epidemiology 
In cross-sectional studies, approximately one-third of patients with SLE has evidence of 
subclinical atheroma plaques in the carotid or coronary arteries (Asunuma et al., 2003) and 
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autopsy findings have showed an even higher prevalence of subclinical atherosclerosis 
(Bulkley & Roberts, 1975). More than 20% of SLE patients who had been on steroids for 
more than one year before death had a 50% occlusion of at least one major coronary artery. 
In a cohort of women with SLE, in whom 15% had already a cardiovascular event, 40% had 
at least one focal carotid artery plaque, a higher frequency than would be expected among 
healthy women (Manzi et al., 1999). Not surprinsingly, the common carotid intima-media 
thickness (IMT) of patients with a history of cardiovascular disease is greater than that of 
SLE patients who had no such history and of healthy volunteers controls (Svenungsson et 
al., 2001). Using photon emission computed tomography (SPECT) and dual isotope 
myocardial perfusion imaging (DIMPI), 40% of all women with SLE and 35% of women 
with SLE and no history of coronary artery disease had abnormalities in myocardial 
perfusion, reinforcing the idea of a high prevalence of early coronary artery disease (Bruce 
et al., 2000).  Also, coronary-artery calcification, as detected by electron-beam computed 
tomography (Roman et al., 2003), occurs more frequently and at a younger age in patients 
with SLE than in healthy controls. Aortic stiffness overall and at any level of the aortic artery 
was higher in patients with SLE than in controls, even after adjusting for age (Roldan et al., 
2010). Furthermore, increased aortic stiffness seems to be an early manifestation of lupus 
vasculopathy that seems to precede the development of hypertension and atherosclerosis. 
Whether we consider the SLE context or not, better biomarkers for measuring disease 
burden are needed. They should be non-invasive, have a good sensitivity and specificity, 
predict disease in asymptomatic individuals and be available for widespread application.  
In clinical practice, diagnosis of atherosclerosis is usually made after the presence of 
symptoms. Pre-symptomatic screening could identify subclinical disease, allowing for a 
more aggressive treatment of the different atherothrombotic risk factors.  
3.1.2 Atheroma formation  
Atherosclerosis is not an age-related process with passive accumulation of lipids in the 
vessel wall. It must be understood as a dynamic and complex biochemical and anatomical 
process. It is characterized by changes in lipoprotein metabolism, activation of the 
immune system and consequent proliferation of smooth-muscle cells, atheroma formation 
and arterial narrowing. In atheroma formation, inflammation and autoimmunity are at 
the forefront of the initiation, progression, and rupture of the plaque (Libby et al., 2010; 
van Leuven et al., 2008). Patients suffering from chronic inflammatory diseases have 
accelerated atherosclerosis, and the high level of inflammation to which patients with 
auto-immune diseases are exposed may induce and accelerate endothelial cell injury. 
Furthermore, biomechanic shear forces enhanced by classic cardiovascular risk factors, 
such as hypertension, hypercholesterolemia, diabetes and smoking are known to 
contribute to endothelium dysfunction (Ando & Yamamoto, 2011). In fact, the earliest 
manifestation of atherothrombosis can be the result of a single disturbance on the 
physiologic pattern of blood flow at an arterial bending on bifurcation site. 
Endothelium regulates anti-inflammatory, mitogenic and contractility activities of the 
vessel wall; also, it has a role in the the hemostatic process within the vessel lumen. A 
dysfunctional endothelium is characterized by an increase in oxidative stress. It facilitates 
oxidation, the uptake of circulating lipoproteins by monocytes, and the migration of these 
cells to the vessel wall, resulting in the proliferation of smooth muscle cells. The 
expression of adhesion molecules (such as ICAM and VCAM) induces the binding of 
monocytes to the endothelial wall (Lusis, 2000). This, when submitted to shear stress 
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forces is also susceptible to permeation and subendothelial accumulation of 
apolipoprotein-B-containing lipoproteins, such as low density lipoproteins (LDL) and 
remnant lipoproteins,  that become targets for oxidative and enzymatic attack. After 
monocyte-endothelial binding takes place, the blood cells are internalized and 
differentiated into macrophages. Retained pro-atherogenic LDL leads to an enhanced 
selective leukocyte recruitment and attachment to the endothelial layer, further 
contributing to their transmigration across the endothelium into the intima. Lipoprotein 
uptake promotes the accumulation of lipid droplets in the cytoplasm of the macrophages, 
transforming them into foam cells. The consequent inflammatory response leads to the 
recruitment of more monocytes, T cells, mast cells and neutrophiles. A fibrous cap is 
produced by collagen secreting myofibroblasts that populate the intima, and the 
developing lesion is contained, most of the times, by a fibrous cap. At the beginning, the 
atherosclerotic lesions are asymptomatic and not at risk for rupture and induction of 
thrombosis. Atheroma lesions submitted to a chronic inflammatory state will become 
unstable and may result in an acute vascular event (Virmani et al., 2002). Within those 
plaques, apoptotic macrophages will suffer necrosis and perpetuate inflammation, with 
the formation of necrotic cores. These vulnerable or unstable plaques may rupture, 
exposing pro-coagulant and pro-thrombogenic molecules into the intima and initiating 
platelet activation and aggregation. This, in turn, will lead to thrombosis and to the 
clinical manifestation of atherothrombotic disease.  
Inflammation plays a major role during all stages of atherosclerosis: endothelial 
dysfunction, endothelial and cytokine activation, recruitment of inflammatory cells, 
macrophage uptake of oxidized low-density lipoprotein (oxLDL), development of fatty 
streaks and fibrous plaque, and finally plaque rupture. Being so, it becomes obvious why 
SLE and atherosclerosis are so closely related. 
3.1.3 Lipids and humoral response towards lipoproteins 
Lipid abnormalities are one of the major contributors for atherosclerosis in SLE and different 
patterns of dyslipoproteinemia have been reported in this disease (Ilowite et al., 1988; 
Svenungsson et al., 2003). Dyslipoproteinemia in active lupus is characterized by depressed 
high density lipoprotein cholesterol and apolipoprotein A1 (ApoA1) with elevated very low 
density lipoprotein cholesterol (VLDL) and triglyceride; on the other hand, the 
dyslipoproteinemia associated with corticosteroid treatment is characterized by increased 
total cholesterol, VLDL, and triglycerides. The pattern of dyslipoproteinemia typical of SLE 
is closely related to disease activity. An enhanced activity in the TNFalpha/soluble TNF-
receptor system seems to be an important underlying factor (Svenungsson et al., 2003). 
Oxidative stress is also a key factor in atherogenesis, and it is increased in patients with SLE. 
Interactions between anticardiolipin (aCL) antibodies and anti-oxidant endothelial cells 
antibodies with the production of pro-oxidant substances suggestes that the interactive 
mechanisms linking plasma lipoproteins, the immune system, and the endothelium are one 
of the missing links that can unveil atheroma plaque formation in SLE. Oxidation profile in 
SLE is reflection of a pro-oxidant status and the presence of aCL antibodies is just one of the 
potential contributors. A direct effect of aCL antibodies with endothelial cells (inducing 
inducible nitric oxide synthase expression) leads to an enhanced peroxynitrite synthesis, a 
pro-oxidant substance, associated with vascular dysfunction and atherogenesis (Delgado 
Alves et al., 2005). 
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The primary lipid components involved in atherosclerosis are lipoproteins. Among these, 
low-density lipoprotein (LDL) and high-density lipoprotein (HDL) assume a central role. 
HDL are thought to have an anti-atherothrombogenic effect by stimulating endothelial nitric 
oxide and inhibiting oxidative stress and inflammation (Yuhanna et al., 2001), thus 
preventing LDL oxidation. LDL is the most pro-atherogenic lipoprotein, due to its ability to 
capture free radicals becoming itself a powerful pro-oxidant. HDL-associated ApoA1 has 
known anti-inflammatory properties (Ashby et al., 1998; Hyka et al., 2001) by promoting 
reverse cholesterol transport from macrophages in vivo as well as by blocking contact 
mediated activation of monocytes by T lymphocytes. Its anti-atherosclerotic actions is also 
associated with the stabilization of  paraoxonase  (James & Deakin, 2000). Paraoxonase is an 
anti-oxidant enzyme that prevents the formation of lipid peroxidation products, such as 
oxLDL. Higher paraoxonase activity is associated with a lower incidence of cardiovascular 
events (Soran et al., 2009).  
HDL has several other antiatherogenic properties, including the transport of cholesterol 
from peripheral tissues to the liver. The concept that macrophage-cholesterol efflux has a 
significant role in cardiovascular disease prevention was recently suggested by the finding 
of a strong inverse association between HDL-mediated cholesterol efflux from macrophages, 
carotid intima media thickness (IMT) and the likelihood of coronary heart disease (Khera et 
al., 2011). These effects were shown to be independent of HDL-cholesterol level. 
Nevertheless, low levels of HDL increase the cholesterol burden and macrophage-driven 
inflammation, being strongly associated with the risk of coronary artery disease. Another  
condition that increases that risk involves the conversion of HDL to a dysfunctional form 
that is no longer cardioprotective (Barter et al., 2004), but instead acquire a pro-
inflammatory and pro-oxidant phenotype promoting atherosclerosis (Delgado Alves et al., 
2002, 2009). Regardless of all these data, the underlying mechanisms are still unclear, and no 
widely accepted methods for determining HDL function have been recognized. Other 
possible mechanisms for HDL dysfunction may be the increased glycation with the 
consequent ApoA1 multimerization and decreased phospholipid content (Parker & Cho, 
2011). This proinflammatory form of HDL (piHDL) has been described in SLE (Navab et al., 
2001) High levels of piHDL increases the risk of developing subclinical atherosclerosis in 
SLE (MacMahon et al., 2009).  
A new concept has merged recently that might account for the higher risk of atherosclerosis 
in SLE: the humoral response towards HDL. It has been confirmed the presence of IgG 
antibodies towards HDL and its main protein component ApoA1 in patients with SLE. By 
interfering with the anti-atherogenic properties of HDL, anti-HDL and ApoA1 antibodies 
enhance oxidative stress and the consequent SLE-related atherosclerotic lesions. Anti-HDL 
antibodies are associated with decreased paraoxonase activity, increased biomarkers of 
endothelial dysfunction (nitric oxide, adhesion molecules VCAM-1 and ICAM-1), reduced 
total antioxidant capacity, and also increased disease-related damage and activity (Batuca et 
al., 2009). Both anti-HDL and anti-apolipoprotein A1 antibodies cross react with aCL. 
Theoretically, anti-HDL and anti-ApoA1 antibodies that cross react with aCL antibodies 
may contribute to endothelial dysfunction by favouring the oxidation of LDL. 
Anti-ApoA1 antibodies have also been described in acute coronary syndromes (Vuilleumier 
et al., 2008), and they be potential markers of plaque instability (Montecucco et al., 2011).   
LDL is the major cholesterol carrying lipoprotein in plasma and may exist in different forms. 
OxLDL injures cells in artery walls, and promotes atheroma formation (Colles et al., 2001; 
Hessler et al., 1979). Small dense LDL, when compared with its larger, normal-size 
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counterpart, is more easily oxidized, has a higher affinity for extracellular matrix, and is 
subject to a higher degree of retention in the arterial wall (Berneis & Krauss, 2002; Hurt-
Camejo et al., 2001; Packard & Sheperd, 1997). Also, smaller LDL has reduced binding to 
LDL receptors (Chapman et al., 1998) and a longer “half-life”. These facts may lead to a 
greater degree of structural modification, which further increases its atherogenic profile. 
In SLE, antibodies to oxidized LDL (anti-oxLDL) have been demonstrated in up to one half 
of patients with SLE (Romero et al., 1998). Also, anti-oxLDL antibody levels correlate with 
complement activation, disease activity scores, anti-double-stranded DNA antibody titres 
(Gómez-Zumaquero et al., 2004)  and were found to facilitate the formation of foam cells( 
Matsuura et al., 2006) 
3.1.4 Inflammation and acute response 
It is already established that inflammation plays a pivotal role in the pathogenesis of 
atherosclerosis. It mediates several of the stages of atheroma development from initial 
leukocyte recruitment to eventual rupture of the unstable atherosclerotic plaque. SLE is 
characterized by a low-grade persistent pro-inflammatory state, present not only during 
flares but also during stable disease. The chronic burden of activated inflammatory 
mediators may have a considerable impact on endothelial cell function and blood 
coagulation. Several inflammatory circulating intermediates in SLE have been identified as 
highly atherogenic, such as IL-1, IL-6, IL-18, monocyte chemotatic protein 1, interferon Ǆ and 
TNFǂ, among others (Asanuma et al., 2006; Blake &Ridker, 2001; Aringer & Smolen, 2004). 
C-Reactive protein (CRP) is an acute phase protein that plays a major role in the regulation 
of the inflammatory response. It has been implicated in the promotion of both leukocyte 
adhesion and migration and also in vascular endothelial dysfunction by inducing adhesion 
molecules, chemokines and cytokines(Pasceri et al., 2000, 2001). Levels of C-reactive protein 
(CRP) have been shown to be predictive of cardiovascular disease in the general population 
(Ridker et al., 2002). High-sensitivity CRP and ICAM-1 have been associated with increased 
coronary artery calcification in SLE patients (Kao et al., 2008). The interaction of anti-
monomeric CRP with monomeric CRP in blood vessel walls may also contribute to 
development of cardiovascular disease in SLE (O’Neill et al., 2007). 
As compared with other auto-immune diseases, such as rheumatoid arthritis, the magnitude 
of CRP elevation is less important. It has been proposed that the relatively low CRP levels in 
SLE patients can be explained by increased clearance or decreased production of this 
protein. Autoantibodies to CRP in SLE patients support its increased clearance (Bell et al, 
1998; Sjowall et al, 2004); however, the plasma clearance rate of CRP is the same in patients 
with active lupus and normal individuals, which makes this hypothesis less likely (Vigushin 
et al, 1993).  
3.1.5 Insulin resistance and the metabolic syndrome  
The metabolic syndrome is a new defined cluster of risk factors associated with increased 
insulin resistance, higher risk of developing type II diabetes mellitus and cardio and 
cerebrovascular events. It is an independent predictor of cardiovascular morbidity and 
mortality. These risk factors include abdominal obesity, pro-atherogenic dyslipidemia and 
elevated blood pressure. Even though individually these abnormalities may contribute little, 
as a risk-factor cluster it is very important and aggressive treatment should be considered in 
these patients. It is estimated that this syndrome may affect 20-25% of the overall population 
in the United States and the prevalence increases with age (Ford et al., 2002).  
www.intechopen.com
 
Systemic Lupus Erythematosus 
 
144 
Insulin resistance is characterized by an impaired response to insulin in several insulin-
sensitive tissue, such as muscle, liver, fat and endothelium (Simonson et al., 2005). Insulin has 
anti-inflammatory properties, mainly due to its ability to suppress several proinflammatory 
transcription factors, such as nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) , early growth response protein 1 (Egr-1) and activator protein 1 (AP-1) (Aliada et al., 
2002). Insulin resistance is a main contributor to the increased cardiovascular risk attributed to 
the metabolic syndrome (Hanley et al., 2002). There is a link between high levels of 
proinflammatory cytokines and cardiovascular disease through metabolic pathways. The exact 
mechanisms linking insulin resistance and inflammation are not fully established. A possible 
candidate is TNF- ǂ. It is over-expressed in the adipose tissues of animal models of obesity 
(Hotamisligi et al., 1993). Adipose tissue act as an endocrine secretory gland, producing 
several inflammatory mediators, responsible for a pro-inflammatory state and thus to an 
increased cardiovascular risk (Després & Lemieux, 2006).   
Tumor necrosis factor-ǂ (TNF-ǂ), IL-1ǃ, IL-4, IL-6, IL-11, Interferon-Ǆ (INF-Ǆ), acting on 
sensitive adipocytes, can lead to the activation of inflammatory signaling cascades (Rajala & 
Sherer, 2003). As a response to fat activation, there is enhanced expression and secretion of 
several acute phase reactants and also mediators of inflammation, such as TNF-ǂ, IL-1ǃ, IL-
6, IL-8, IL- 10, prostaglandin E2 (PGE2). Leptin, adiponectin, and resistin (Fain et al., 2004) 
can  perpetuate in the highly pro-inflammatory state.  
SLE is associated with an increased prevalence of the metabolic syndrome (El-Magdami et 
al., 2006). The frequency of metabolic syndrome amongst patients with SLE varies from 
16,7% in Mexico(Zonana-Nacah e tal., 2008), 28,6 % in Argentina to 29,4 % in USA (Chung et 
al., 2007) and 32,1 % in Brazil (Telles et al., 2010), with other cohorts showing similar results. 
Other metabolic-associated changes such as insulin resistance, premature menopause, renal 
impairment and high triglyceridemia also occur more frequently in SLE. Controversy still 
remains regarding the exact role of metabolic syndrome in predicting long-term risk for 
coronary heart disease in SLE. The major benefit in recognising this syndrome in the context 
of SLE is related to the identification of patients more in need for lifestyle interventions and 
specific therapeutic approach.  
There is no clear association between treatment with steroids and the development of 
metabolic syndrome (Telles et al., 2007. However, prednisone in dosages higher than 10 
mg/ day and high dosages of intravenous methylprednisone has been previously associated 
with this condition (Négron et al., 2008). These findings are still not definitive as they can be 
a reflection of lupus activity and severity. In fact, low-dose steroids may still be of value, 
due to its anti-inflammatory effects. 
3.1.6 Traditional risk factors for cardiovascular disease in SLE  
A patient with SLE and cardiovascular disease has on average one less traditional risk factor 
than people in the general population with a similar cardiovascular condition (Bruce, 2005; 
Urowitz et al., 2007) and the baseline 10-year coronary heart disease and stroke risk (after 
adjusting for Framingham score) for all patients with SLE is 7.5–17-fold higher (Esdaile et 
al., 2001). This is one of the reasons why the relative importance of the individual traditional 
risk factors differs between patients with SLE and the general population. 
Hypertension 
Hypertension is a predictor of mortality and vascular events in SLE (Petri et al., 1992; 
Rahman et al., 2000). It is more common than in the general population with a relative risk 
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of 2.59 (95% CI 1.79–3.75) (Bruce et al., 2003), independently of whatever treatment for SLE 
is being administred. 
Smoking 
Smoking, a well known risk factor for atherosclerosis, is not more frequent in patients with 
SLE than in the general population (RR 0.86, 95% CI 0.59–1.24) (Boyer et al., 2011), but in the 
Systemic Lupus International Collaborating Clinics registry (SLICC) (Urowitz et al., 2008) 
the prevalence of smokers increased from 13.7% at baseline to 18.7%. 
Dyslipidemia  
Hpercholesterolemia in lupus patients is associated with an 18-fold increased risk of 
myocardial infarction as compared with the general population (Fischer et al., 2004).   
Body composition and low physical exercise 
Patients with lupus are more likely to have a sedentary lifestyle, with consequent obesity 
and hypercholesterolemia (Petri et al., 1992). Low physical activity is associated with 
increased subclinical atherosclerosis and proinflammatory HDL levels in patients with SLE. 
Despite the common presence of fatigue as a symptom of the disease, there is reason to 
believe that exercise should be included in the rehabilitation of patients with mild to 
moderate SLE (Yuen et al., 2011). Exercise, if well tolerated, may reduce the risk of 
atherosclerosis in SLE (Volkmann et al., 2010). 
3.1.7 Other risk factors 
Treatment of SLE and its most common co-morbidities has become more and more complex 
with drug interactions and side effects becoming a very important issue. Apart from the 
classical complications of steroid and immunosuppressive treatment, new associations 
between drugs and clinical adverse effects have been identified. Azathioprine, as an 
example, was associated with arterial events (hazard ratio of 1.45 (95% CI 1.21–10.4) (Toloza 
et al., 2004) and with the presence of carotid plaques (Ahmad et al., 2004). Although we 
should keep these results in mind, the fact is that azathioprine is used in more active disease 
and it may be just a surrogate for more severe inflammation.  
Hyperhomocysteinemia is a well known risk factor for cardiovascular disease and it is a 
possible marker of atherosclerosis progression and more-active lupus (Bultink et al., 2005; 
Kianai et al., 2007; Roman et al., 2007). It decreases the availability of endothelial cell-
derived nitric oxide, impairs endothelial-dependent vasodilatation, induces oxidative stress, 
and increases the risk of thrombosis (Maron & Loscalzo, 2009). Homocystein actions on 
endothelial cells are partly mediated by asymmetric dimethylarginine (ADMA), an intrinsic 
inhibitor of nitric oxide synthase (Stuhlinger et al., 2003).  High levels of ADMA have been 
described in patients with renal and heart failure, diabetes mellitus, hypertension, and acute 
coronary events and may predict stroke, coronary artery disease, and also cardiovascular-
related death (Laier et al. 2008; Wilson et al., 2008). Among patients with SLE, higher ADMA 
levels are linked to a higher prevalence of cardiovascular disease.  
Hyperuricemia correlates with arterial stiffness and inflammation markers in patients with 
SLE without symptomatic atherosclerotic disease. It has been showed that women with SLE 
and hyperuricemia have a high risk cardiovascular profile with metabolic syndrome and 
renal failure. 
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3.2 Vasculitis 
In the absence of clinically significant coronary atherosclerosis, two other major mechanisms 
of vascular damage may occur: vasculitis and thrombosis. 
The prevalence of vasculitis in SLE patients ranges from 11% to 20% (Cardinali et al., 2000; 
Wisnieki, 2000). Small vessels (both arteries and venules) of the skin are the most commoly 
involved (Gonzalez-Gay et al., 2005); medium-sized vessel involvement is less frequent 
(D’Cruz et al., 1993), and large vessel involvement is rare (Goldberger et al., 1992). Although 
vasculitis presents mainly as cutaneous lesions, the clinical spectrum is wide, and 
lifethreatening ischemic injury may result from vasculitis of medium-sized vessels in the 
gastrointestinal, cardiac, pulmonary, or cerebrovascular regions (D’Cruz, 1998). 
Coronary vascular damage may be related to coronary arteritis, affecting preferentially 
small-size coronary arteries (Bulkley & Roberts, 1975) or, rarely, the medium-size coronary 
arteries (Bonfiglio et al., 1992); and/ or coronary artery thrombosis. Acute myocardial 
infarction due to coronary arteritis is reported in SLE, although the incidence is very low.  
Immune complex deposition and complement activation play important roles in the 
pathogenesis of vasculitis in general and coronary arteritis in particular. In patients with both 
SLE and antiphospholipid syndrome, microvascular thrombi of the coronary circulation, with 
discrete atherosclerosis and vasculitis, have been observed (Brown et al., 1988).  
The distinction between atherosclerosis and arteritis is a difficult task, because coronary 
vasculitis often occurs in the absence of a clinical SLE flare and also with minimal serologic 
evidence of disease activity (Wilson et al., 1992).  
Central nervous system (CNS) vasculitis in the context of SLE is rare, although it has been 
found in autopsies in SLE in 7-12% of cases (Johnson & Richardson, 1968; Ellis & Verity,  
1979).  
Stroke (both ischaemic and haemorrhagic) and SLE cerebral vasculopathy are far more 
frequent. While ischaemic stroke in SLE is strongly associated to antiphospholipid 
syndrome, atherosclerosis (Bruce, 2005) and Libman-Sacks endocarditis (Moyassaki et al., 
2007), factors that contribute to hemorrhagic stroke are less clear. 
The predominant pathology finding in CNS vessels in SLE patients is a noninflammatory 
small vessel vasculopathy involving small arterioles and capillaries. At autopsy, 50% of the 
patients have cerebral vasculopathy, characterized by hyaline thickening and eosinophilia of 
the vessel wall, fibrinoid degeneration without vasculitis, and endothelial proliferation, 
sometimes accompanied by microhemorrhages (Devinsky et al., 1988; Ellison et al. 1993; 
Hanly et al., 1992).  
3.3 Thrombosis 
Thrombotic events are reported in 7-12% of patients with SLE (Somers et al., 1999). During 
the first year of disease, the incidence of both arterial and venous thrombotic events 
increases. Several reasons have been pointed out, and include  aPL antibodies, circulating 
immune complexes, high levels of disease activity, and chronic inflammation (Manger et al., 
2002). When associated with SLE, antiphospholipid syndrome is a relevant predictor of 
organ damage and death in patients (Ruiz-Irastorza et al., 2004). Anti-cardiolipin (aCL) 
antibodies, lupus anticoagulant (LAC) and anti-beta2-glycoprotein 1 antibodies (anti-B2GPI) 
are detected in approximately one-third of patients with SLE (Love & Santoro, 1990), 
especially in the context of the antiphospholipid syndrome. The best predictors for 
thrombotic events in SLE are persistent aPL antibodies, the presence of LAC (Somers et al., 
2002), and high titers of aCL antibodies (Ginsburg et al., 1992).   
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Not all thrombotic phenomena are associated with the presence of aPL antibodies and some 
patients may develop venous and arterial thrombosis without aCL positivity.  The relevance 
of traditional and SLE-related thrombotic risk factors in aPL positive patients is still under 
investigation. Most of the patients with SLE and aPL antibodies who developed thrombosis 
had other thrombotic risk factors (Erkan et al., 2007). Interestingly, after adjusting for other 
risk factors, SLE itself remains independently associated with thrombotic events (Bruce, 
2005). Thrombosis is frequent in early SLE and is associated with a significant mortality; 
therefore, the identification of possible modifiable risk factors and the establishment of 
efficacious strategies of prevention and treatment are vital. 
4. Treatment 
The impact of cardiovascular disease has been under-recognized in the context of SLE, with 
limited attention on aggressive management of possible modifiable risk factors. Despite a 
general awareness of coronary vascular disease in SLE patients, physicians do not address 
risk factors in a comprehensive fashion. Also, the management of conventional 
cardiovascular risk factors such as diabetes mellitus, smoking, hypercholesterolemia and 
hypertension is not at the same level of non-SLE patients. This is reinforced by the fact that 
recruiting and retaining patients with SLE for clinical trials regarding preventive measures 
has been proven to be extremely difficult.  
It is therefore of great importance to identify in each patient the modifiable risk factors and 
introduce in clinical practice guidelines to help clinicians reducing long-term cardiovascular 
morbidity and mortality. In this chapter, we analyze the potential impact of some of the 
most commonly used drugs in SLE and their effects in the cardiovascular system.  
The general approach suggested in the overall population for primary and secondary 
prophylaxis of vascular disease should be proposed to every patient and should include 
(table 2): 
4.1 Corticosteroids: Are they good or bad for lupus? 
Corticosteroids still remain a first line treatment for lupus, despite having numerous 
detrimental side effects on blood pressure, blood glucose and lipid profile (Manzi et al., 
2000).  Corticosteroids have a particular deleterious effect on the heart (Bulkley et al., 1975). 
Prednisone dosage superior to 7,5 mg/d increases insulin levels, a risk factor for 
cardiovascular disease (Karp et al., 2008) and total cholesterol, triglycerides and 
apolipoprotein B levels increase significantly with a daily prednisone dose higher than 10 
mg (Petri et al., 1992). The estimated 2-year coronary risk for a patient treated with anved an 
average dosage of 30 mg/day of prednisone for 1 year, is approximately 60% higher than it 
would be for a patient with the same levels of SLE activity and similar risk factors who 
received no corticosteroids (Karp et al., 2008).   
When compared to a baseline chronic inflammatory status, low dose corticosteroids may 
exert an anti-inflammatory action which might be beneficial. In fact, such exposure may 
improve the lipid profile and increase insulin levels, whithout having a negative effect on 
blood pressure and atherosclerosis. A weak association between low-dose corticosteroids 
and cardiovascular risk factors has been established, and identified a dose-related trend for 
increasing major cardiovascular events (Ruyssen-Witrand et al., 2010). Furthermore, 
subclinical atherosclerosis is correlated with lower mean dose of corticosteroids and lesser 
immunossupressants (Roman et al., 2003).  
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C
h
o
le
st
er
o
l 
1. Screening: fasting lipid profile every year; 
2. For LDL cholesterol <2.6 mmol/l: no treatment; 
3. For LDL cholesterol 2.6–3.4 mmol/l: therapeutic lifestyle changes.   
4. Consider statins when LDL is >3.4 mmol/l with or without other risk 
factors; or when LDL is persistently >2.6 mmol/l despite therapeutic 
lifestyle changes. 
H
y
p
er
te
n
si
o
n
 
1. Blood pressure assessments at every visit to the outpatients clinic; 
2. Ideal target is defined as blood pressure at <130 mmHg systolic and 
<80 mmHg diastolic.  
3. If elevated blood pressure (>140 mmHg systolic or >90 mmHg diastolic): 
lifestyle modification.;  
4. If, despite previous measures, the blood pressure is persistently found to be 
elevated:  start antihypertensive medication.  
D
ia
b
et
es
 
m
el
li
tu
s 
1. Regular testing for diabetes (1-2 /year); 
2. In patients with a fasting glucose ≥6.1 mmol/l:  glucose tolerance test and 
lifestyle changes;  
3. Referral to a specialist in diabetes.  
W
ei
g
h
t 
co
n
tr
o
l 
1. Screening for obesity;  
2. Lifestyle changes, exercise programmes and behavioral support;  
3. If, despite efforts, obesity remains, refer to drug/ bariatric surgery by a 
multidisciplinary team. 
Table 2. Summary of some therapeutic interventions. 
There are some important limitations in addressing the role of steroids in cardiovascular 
risk. Corticosteroid use is more common in patients with moderate to severe disease (Bruce, 
2006) and the duration of exposure to this drug may function as a surrogate for disease 
duration. Further work is needed to assess if there are doses or regimes of corticosteroid 
therapy that can optimise their anti-inflammatory effects whilst minimizing their multiple 
adverse effects.  
4.2 Statins 
Pleotropic actions of hydroxyl-3-methylglutaryl coenzyme A (HMG-CoA) inhibitors 
(statins) have been thourougly reported and is now accepted that their benefits go beyond 
cholesterol lowering and include immunomodulatory and immunossupressive properties. 
Statins inhibit HMG-CoA reductase, an enzyme that converts HMG-CoA to mevalonate, a 
fundamental step in cholesterol synthesis. The mevalonate pathway is involved in 
posttranslational modification of cell-signaling proteins during cell division and maturation, 
with inhibition of proinflammatory effects. It then promotes anti-inflammatory activities 
through the direct inhibition/activation of chemokyne, cytokine-, and acute-phase reactant-
driven intracellular pathways in several cell types involved in inflammation. Statins 
modulate the activity of cells involved in both innate and adaptative immune responses, 
affecting the production of cytokines and cellular adhesion molecules (e.g. ICAM-a, IL-6, 
TNF-ǂ, IL-1 and selectin levels (Mira & Mañes, 2009) and have an antithrombotic effect by 
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inhibiting platelet activation (Ferroni et al., 2006). In the general population, statins have 
shown efficacy in primary and secondary prevention of acute myocardial infarction and 
stroke (Amarenco et al., 2006; Ridker et al., 2008).  
Following the identification of their mechanisms of action, statins became a potential drug 
for treating SLE patients despite cardiovascular involvement. Low dose rosuvastatin 
induced a significant reduction in LDL and CRP after 12 months treatment (Mok et al., 
2011). In patients with low disease activity, rosuvastatin decreased plasma levels of 
endothelial activation markers such as P-selectin and VCAM-1. Unexpectedly, in 2011, the 
results from the Lupus Atherosclerosis Prevention Study (Petri et al., 2011) offered no 
evidence that atorvastatin could reduce markers of subclinical atherosclerosis or disease 
activity over 2 years and the anti-inflammatory effects of statins observed in the general 
population were not replicated in this SLE clinical trial. However, comments were raised 
regarding the homogeneity of both treatment arms which may limit the final interpretation. 
Importantly, there was no information about the treatments received by patients during the 
2 years follow-up, regarding the use of prednisone, immunosupresive agents and 
hydroxychloroquine, all of them having a direct effect on inflammation and disease activity 
and potentially on subclinical atherosclerosis. Hence, the negative results in this clinical trial 
could be caused by an imbalance in the use of these drugs in both arms, rather than by the 
lack of efficacy of atorvastatin. 
4.3 Low dose salicylic acid  
Most of SLE patients with aPL, but without a history of thrombosis, do not receive any 
preventive therapeutic, while some receive low dose salicylic acid (ASA) (Kamashta, 2000). 
Prophylactic treatment with ASA in SLE patients may prevent both arterial and venous 
thrombotic manifestations, especially in patients with positive aPL (Wahl et al., 2000). In 
fact, ASA decreases the probability of thrombosis in asymptomatic individuals with aPL 
(Erkan et al., 2002). The use of low-dose ASA has been recommended by the expert 
committee in the recent European League Against Rheumatism guidelines for the 
management of SLE (Bertsias et al., 2008).  
4.4 Hydroxychloroquine 
Hydroxychloroquine is an anti-malarial drug also used to treat SLE,  Sjögren's syndrome 
and other immune mediate diseases. Several mechanisms have been proposed to explain its 
beneficial effect, which is not fully established. Hydroxychloroquine can inhibit the binding 
of antiphospholipid antibody–ǃ2-glycoprotein I complexes to phospholipid bilayers (Rand 
et al., 2008), reverse platelet activation induced by human IgG aPL antibodies (Espinola et 
al., 2002), and reduce of aPL antibody–induced thrombosis (Edwards et al., 1996). There is 
no consistent data regarding whether this antithrombotic effect is present both for arterial 
and venous events. 
A beneficial effect on serum lipid levels, including patients taking corticosteroid therapy 
(Borba et al., 2001; Hodis et al., 1993; Sachet et al., 2007; Tam et al., 2000), was shown by a 
few observational studies. However, the strenght of evidence supporting a clinically 
meaningful beneficial effect was rated as low. Also, there is no data supporting any 
protective effect of this drug on the development of metabolic syndrome (Ruiz-Irastorza et 
al., 2010). 
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Regarding the effect of hydroxychloroquine on atherosclerosis, most studies are limited by 
the low consistency and lack of specific design (Ahmad et al., 2007; Maksimowicz-
McKinnon et al, 2006). The effect was not quantified in most cases and the exposure to 
hydroxychloroquine has been heterogeneously defined, without taking into account the 
time of exposure or a possible dose effect. 
Because of its beneficial effects on reducing SLE activity and mortality, most of the authors 
recommend hydroxychloroquine for most patients with SLE, starting as soon as the 
diagnosis is made. Its application for the specific prevention of thrombosis and treatment of 
atherosclerosis requires validation in future clinical trials. 
4.5 B-cell depletion therapy 
Rituximab, a drug that had no previously documented lipid-lowering effect, was recently 
investigated in patients with SLE who had failed standard immunosuppressive therapy 
(Pego-Reigosa et al., 2010). An increase in HDL cholesterol and a fall in the total 
cholesterol/HDL ratio and triglyceride levels was documented in a significant proportion of 
the 12 patients studied. Furthermore, this improvement in lipid profile mirrored a decrease 
in disease activity; this suggests a positive effect of rituximab related to a reduction in the 
overall high inflammatory status. Still, larger prospective studies should aim to evaluate if 
this observed favorable effect contributes to a lower incidence of cardiovascular events. 
5. Conclusion 
Patients with SLE are at increased risk for cardiovascular complications. Atherosclerosis 
occurs prematurely in patients with systemic lupus erythematosus and is independent of 
the traditional risk factors for cardiovascular disease. Premature atherosclerosis has 
emerged as a leading cause of morbidity and mortality in SLE. Traditional risk factors, such 
as hypertension, smoking, diabetes, obesity and dyslipidemia are common in SLE but they 
fail to explain entirely the atherosclerotic burden found in these patients. Increased 
understanding of the mechanisms underlying vascular damage, plaque formation and 
stability, and thrombosis, will greatly facilitate the long-term care of patients with lupus. 
The clinical profile of patients with lupus and atherosclerosis suggests a role for disease-
related factors in atherogenesis and underscores the need better trials targeting 
atherosclerosis in a specific fashion. 
An early identification of subclinical atherosclerosis in SLE is warranted to help to identify 
patients with higher risk to undergo major vascular complications, who might benefit from 
more aggressive treatment and lifestyle modifications.  
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